摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(3,5-Difluorophenyl)-3-[4-methoxy-3-(2-piperidin-1-ylethoxy)phenyl]imidazol-2-one | 561277-52-9

中文名称
——
中文别名
——
英文名称
1-(3,5-Difluorophenyl)-3-[4-methoxy-3-(2-piperidin-1-ylethoxy)phenyl]imidazol-2-one
英文别名
——
1-(3,5-Difluorophenyl)-3-[4-methoxy-3-(2-piperidin-1-ylethoxy)phenyl]imidazol-2-one化学式
CAS
561277-52-9
化学式
C23H25F2N3O3
mdl
——
分子量
429.467
InChiKey
MEFXMBYDODZESE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    31
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    45.2
  • 氢给体数:
    0
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    1-(3,5-Difluorophenyl)-3-[4-methoxy-3-(2-piperidin-1-ylethoxy)phenyl]imidazol-2-one 在 palladium on activated charcoal 氢气 作用下, 以 乙醇 为溶剂, 反应 16.0h, 生成 1-(3,5-Difluorophenyl)-3-[4-methoxy-3-(2-piperidin-1-ylethoxy)phenyl]imidazolidin-2-one
    参考文献:
    名称:
    A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists
    摘要:
    Bisaryl cyclic ureas have been identified as high affinity 5-HT2C receptor antagonists with selectivity over 5-HT2A and 5-HT2B. Compounds such as 8 and 22 have shown oral activity in a centrally mediated pharmacodynamic model of 5-HT2C function in rodents. (c) 2005 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2005.08.004
  • 作为产物:
    描述:
    2-甲氧基-5-硝基苯酚 在 palladium on activated charcoal 盐酸氢气potassium carbonate 作用下, 以 乙二醇二甲醚乙醇二氯甲烷甲苯 为溶剂, 20.0 ℃ 、101.33 kPa 条件下, 反应 92.0h, 生成 1-(3,5-Difluorophenyl)-3-[4-methoxy-3-(2-piperidin-1-ylethoxy)phenyl]imidazol-2-one
    参考文献:
    名称:
    A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists
    摘要:
    Bisaryl cyclic ureas have been identified as high affinity 5-HT2C receptor antagonists with selectivity over 5-HT2A and 5-HT2B. Compounds such as 8 and 22 have shown oral activity in a centrally mediated pharmacodynamic model of 5-HT2C function in rodents. (c) 2005 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2005.08.004
点击查看最新优质反应信息

文献信息

  • [EN] CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY<br/>[FR] DERIVES CYCLIQUES D'UREE POSSEDANT UNE ACTIVITE DE RECEPTEURS 5-HT2C
    申请人:GLAXO GROUP LTD
    公开号:WO2003057220A1
    公开(公告)日:2003-07-17
    Compounds of formula (I) or a pharmaceutically acceptable salt thereof, having 5HT2C receptor activity, are disclosed: wherein a is 0, 1, 2, 3, 4 or 5; b is 1, 2 or 3; Y is nitrogen or carbon; A is oxygen, nitrogen, -CONH-, -NHCO- or together with R2 form a benzoxazolone group; R1 is halogen, C¿1-6?alkyl, C1-6alkoxy, C1-6alkylthio, hydroxy, amino, mono- or di-C1-6alkylamino, nitro, CN, CF3, OCF3, aryl, arylC1-6alkyl, arylC1-6alkyloxy or arylC1-6alkylthio; R?2¿ is hydrogen, halogen, C¿1-6?alkyl, C1-6alkoxy, haloC1-6alkyl or haloC1-6alkoxy; R?3¿ is: (i) -NR4R5 where R?4 and R5¿ are independently hydrogen, C¿1-6?alkyl or arylC1-6alkyl; or (ii) an optionally substituted N-linked heterocycle; or (iii) an optionally substituted C-linked heterocycle; ======= is a single bond or a double bond; and X is CH2 or C = O (when ======= is a single bond) or X is CH (when ======= is a double bond). The preparation of these compounds and their use in therapy, especially for a CNS disorder such as depression or anxiety, are also disclosed.
    公开了式(I)的化合物或其药学上可接受的盐,具有5HT2C受体活性:其中a为0、1、2、3、4或5;b为1、2或3;Y为氮或碳;A为氧、氮、-CONH-、-NHCO-或与R2一起形成苯并噁唑酮基团;R1为卤素、C1-6烷基、C1-6烷氧基、C1-6烷基基、羟基、基、单基或双C1-6烷基基、硝基、CN、CF3、O 、芳基、芳基C1-6烷基、芳基C1-6烷氧基或芳基C1-6烷基;R2为氢、卤素、C1-6烷基、C1-6烷氧基、卤代C1-6烷基或卤代C1-6烷氧基;R3为:(i)-NR4R5,其中R4和R5独立地为氢、C1-6烷基或芳基C1-6烷基;或(ii)可选地取代的N-连接杂环;或(iii)可选地取代的C-连接杂环;=======为单键或双键;X为CH2或C = O(当=======为单键时)或X为CH(当=======为双键时)。还公开了这些化合物的制备及其在治疗中的用途,特别是用于中枢神经系统疾病,如抑郁症或焦虑症。
  • Cyclic urea derivatives with 5-ht2c receptor activity
    申请人:Bromidge M Steven
    公开号:US20050154028A1
    公开(公告)日:2005-07-14
    Compounds of formula (I) or a pharmaceutically acceptable salt thereof, having 5HT 2C receptor activity, are disclosed: wherein a is 0,1,2,3,4 or 5; b is 1,2 or 3; Y is nitrogen or carbon; A is oxygen, nitrogen, —CONH—, —NHCO— or together with R 2 form a benzoxazolone group; R 1 is halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, hydroxy, amino, mono- or di-C 1-6 alkylamino, nitro, CN, CF 3 , OCF 3 , aryl, arylC 1-6 alkyl, arylC 1-6 alkyloxy or arylC 1-6 alkylthio; R 2 is hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl or haloC 1-6 alkoxy; R 3 is: (i) —NR 4 R 5 where R 4 and R 5 are independently hydrogen, C 1-6 alkyl or arylC 1-6 alkyl; or (ii) an optionally substituted N-linked heterocycle; or (iii) an optionally substituted C-linked heterocycle; ======= is a single bond or a double bond; and X is CH 2 or C═O (when ======= is a single bond) or X is CH (when ======= is a double bond). The preparation of these compounds and their use in therapy, especially for a CNS disorder such as depression or anxiety, are also disclosed.
    公开了式(I)化合物或其药学上可接受的盐,具有5HT2C受体活性:其中a为0、1、2、3、4或5;b为1、2或3;Y为氮或碳;A为氧、氮、-CONH-、-NHCO-或与R2一起形成苯并噁唑酮基团;R1为卤素、C1-6烷基、C1-6烷氧基、C1-6烷基基、羟基、基、单-或双C1-6烷基基、硝基、CN、CF3、O 、芳基、芳基C1-6烷基、芳基C1-6烷氧基或芳基C1-6烷基;R2为氢、卤素、C1-6烷基、C1-6烷氧基、卤代C1-6烷基或卤代C1-6烷氧基;R3为:(i)-NR4R5,其中R4和R5独立地为氢、C1-6烷基或芳基C1-6烷基;或(ii)可选地取代的N-连接杂环;或(iii)可选地取代的C-连接杂环;=======为单键或双键;X为CH2或C═O(当=======为单键时)或X为CH(当=======为双键时)。还公开了这些化合物的制备及其在治疗中的使用,特别是用于中枢神经系统障碍,如抑郁症或焦虑症。
  • CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY
    申请人:GLAXO GROUP LIMITED
    公开号:EP1465630A1
    公开(公告)日:2004-10-13
查看更多